IRIS
LANDI, DORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.909
EU - Europa 984
AS - Asia 654
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 4
AF - Africa 3
OC - Oceania 3
Totale 6.567
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.902
IT - Italia 421
SG - Singapore 366
IE - Irlanda 207
KR - Corea 177
RU - Federazione Russa 111
CN - Cina 72
DE - Germania 67
GB - Regno Unito 47
UA - Ucraina 33
SE - Svezia 20
FR - Francia 18
FI - Finlandia 15
JP - Giappone 10
CH - Svizzera 9
CZ - Repubblica Ceca 9
IN - India 9
NL - Olanda 9
CA - Canada 7
GR - Grecia 6
PL - Polonia 5
BR - Brasile 3
CO - Colombia 3
ES - Italia 3
IQ - Iraq 3
PK - Pakistan 3
RO - Romania 3
UZ - Uzbekistan 3
AR - Argentina 2
AU - Australia 2
CL - Cile 2
EU - Europa 2
KG - Kirghizistan 2
NG - Nigeria 2
TR - Turchia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
HK - Hong Kong 1
ID - Indonesia 1
IR - Iran 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
MY - Malesia 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
ZA - Sudafrica 1
Totale 6.567
Salva come PNG Salva come JPEG
Città #
Wilmington 1.326
Houston 1.060
Woodbridge 636
New York 358
Singapore 329
Chandler 217
Fairfield 196
Dublin 188
Santa Clara 81
Ashburn 77
Rome 74
Ann Arbor 70
Roebling 65
Seattle 62
Medford 59
Cambridge 56
Moscow 31
Dearborn 29
Lawrence 29
Beijing 25
San Jose 25
Milan 22
San Diego 19
Jacksonville 18
Piove di Sacco 14
Turin 14
Creede 13
London 12
Mülheim 11
Naples 10
Palo Alto 10
Seoul 10
Brno 9
Los Angeles 9
Bologna 8
Florence 8
Inverigo 8
Norwalk 8
Redwood City 8
Zhengzhou 7
Lodi 6
Munich 6
Nanjing 6
Bari 5
Billings 5
Boardman 5
Helsinki 5
Kilburn 5
Palermo 5
Tokyo 5
Atlanta 4
Frankfurt am Main 4
Kunming 4
Lappeenranta 4
Lausanne 4
Nuremberg 4
Saitama 4
Schio 4
Xi'an 4
Bergamo 3
Bogotá 3
Cercenasco 3
Chennai 3
Chiswick 3
Detroit 3
Guangzhou 3
Hounslow 3
Islamabad 3
Karbala 3
Kraków 3
Menlo Park 3
Paris 3
Philadelphia 3
Salo 3
San Francisco 3
Trieste 3
Abuja 2
Athens 2
Bad Bruckenau 2
Basel 2
Bogliasco 2
Brooklyn 2
Cardano al Campo 2
Carugate 2
Castelfidardo 2
Catania 2
Copertino 2
Council Bluffs 2
Del Norte 2
Edmond 2
Essen 2
Falls Church 2
Formia 2
Gunzenhausen 2
Hangzhou 2
Hawkestone Beach 2
La Spezia 2
Lissone 2
Macerata 2
Minneapolis 2
Totale 5.399
Salva come PNG Salva come JPEG
Nome #
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 453
TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis 436
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression 401
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 389
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course 301
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 296
null 289
Safety, tolerability and effectiveness of dimethyl fumarate in multiple sclerosis: an independent, multicenter, real-world study 286
Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis 280
Miscarriage induces reactivation of inflammation in relapsing-remitting multiple sclerosis 276
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis 275
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study 266
Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis 155
Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study 134
Validity of the Italian multiple sclerosis neuropsychological screening questionnaire 131
Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis 120
Functional assessment of outer and middle macular layers in multiple sclerosis 98
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab 93
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 76
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 71
Correction to: Validity of the Italian multiple sclerosis neuropsychological screening questionnaire 64
Assessment of macular function by multifocal electroretinogram in patients with multiple sclerosis treated with fingolimod 64
Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis 62
T-cell responses to SARS-CoV-2 in Multiple Sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-Spike antibody titers 59
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications 55
Patient's point of view on the use of telemedicine in multiple sclerosis: a web-based survey 53
COVID-19: dealing with a potential risk factor for chronic neurological disorders 49
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis 46
Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection 44
Cortical ischemic lesion burden measured by DIR is related to carotid artery disease severity 43
Cognition is related to resting-state small-world network topology: an magnetoencephalographic study 43
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 40
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) in the Italian population 40
What happens after fingolimod discontinuation? A multicentre real-life experience 40
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 36
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course 35
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 34
Complex epileptic palilalia: a case report 33
Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment 33
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 33
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis 32
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 32
Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study 32
Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol 31
Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus 31
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression 30
Ovarian reserve in patients with multiple sclerosis: A systematic review and meta-analysis 29
Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability 29
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders 29
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 28
Skin Thickening of the Scalp and High Signal Intensity of Dentate Nucleus in Multiple Sclerosis: Association With Linear Versus Macrocyclic Gadolinium-Based Contrast Agents Administration 28
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 27
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 27
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study 27
Diagnostic value of JC polyomavirus viruria, viremia, serostatus and microRNA expression in multiple sclerosis patients undergoing immunosuppressive treatment 27
Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells' Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration 27
Diffusion-weighted lesions after carotid artery stenting are associated with cognitive impairment 26
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study 25
fMRI-vs-MEG evaluation of post-stroke interhemispheric asymmetries in primary sensorimotor hand areas 25
Cerebral restorative plasticity from normal ageing to brain diseases: a "never ending story" 24
Cortico-muscular coherence as an index of fatigue in multiple sclerosis 24
Sex effects across the lifespan in women with multiple sclerosis 24
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography 24
A specific anti-COVID-19 BNT162b2 vaccine-induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients 23
Intra-cortical connectivity in multiple sclerosis: a neurophysiological approach 22
Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing???remitting multiple sclerosis 22
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue." 21
COVID-19 vaccine hesitancy among Italian people with multiple sclerosis 21
Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis 20
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis 19
Dorsolateral medullary ischemic infarction causing autonomic dysfunction and headache: a case report 19
Gender-related differences in functional connectivity in multiple sclerosis 19
Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data 18
Thalamocortical sensorimotor circuit in multiple sclerosis: an integrated structural and electrophysiological assessment 17
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis 17
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 17
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 16
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 16
Therapeutic choices and disease activity after 2 years of treatment with cladribine: an Italian multicenter study (CladStop) 15
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT) 14
Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey 13
Exposure to natalizumab during pregnancy and lactation is safe - Yes 12
Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy 11
Treatment modifiers across different regimens of natalizumab treatment in MS: an Italian real-world experience 11
Sars-CoV2 infection in pregnant women with multiple sclerosis 11
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 9
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 8
Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine 6
null 5
null 3
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue." 2
Totale 6.777
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.261
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.261
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020926 0 0 0 0 98 142 132 118 134 113 92 97
2020/20211.050 92 108 105 106 139 122 147 111 34 37 32 17
2021/2022391 31 29 20 40 23 49 16 22 34 29 23 75
2022/20231.192 39 31 304 215 54 188 134 50 78 12 65 22
2023/2024474 104 10 25 23 33 69 35 12 28 23 11 101
2024/2025860 65 399 188 150 58 0 0 0 0 0 0 0
Totale 6.777